Back

Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis

1 September 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (2) Drug therapy Open Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Clara Bonanad Lozano

Research Foundation Hospital of Valencia (INCLIVA), Valencia (Spain)

6 More presentations in this session

Presentation thumbnail
Bempedoic acid in clinical practice.
Doctor J. Vazquez Reguera (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study
Assistant Professor Z. Yang (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
LDL on target - strike early and strike strong... just strike...
Doctor L. Hamann (Faro, PT)
Abstract Slides Video
Presentation thumbnail
VICTORION IMPLEMENT: an observational study of the lipid management landscape in Germany
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Analytical approaches to open label extension (OLE) after cardiovascular outocmes trials: Observations from the FOURIER and FOURIER-OLE trials
Doctor H. Wang (Newbury Park, US)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (2)

The Event

Event poster

ESC Congress 2025

1 September 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
thumbnail
Congress Presentation
Efficacy and safety of alirocumab 300mg in real-world clinical practice: preliminary data from the ALINET Registry
thumbnail
Congress Session
Late-breaking science on pharmacology

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources